A.P. Pharma announces two senior appointments in connection with its lead product candidate, APF530 

A.P. Pharma announces two senior appointments in connection with its lead product candidate, APF530

Dec 18, 2012 (Menafn - M2 EQUITYBITES via COMTEX) --Specialty pharmaceutical company A.P. Pharma Inc APPA on Monday announced the appointment of Joel Schaedler as vice president of market access and Daniel Martin as vice president of marketing.

In his new role Schaedler will be responsible for the company's market access programmes for APF530, the company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. Martin, in his new role, will lead the marketing efforts for APF530.

Schaedler, who has over 17 years of specialty pharmaceutical and healthcare distributor experience, was most recently the senior vice president of business development at P4 Healthcare, which was acquired by Cardinal Health in 2010. Prior to Cardinal Health he served as the regional vice president of sales for Bionicare Medical Technologies. Before that he held positions of increasing responsibilities with Amerisource Bergen Specialty, Centocor (acquired by Johnson & Johnson) and Sanofi-Aventis.

Most recently Martin served as the head of US marketing at Dendreon. Prior to that he spent seven years in positions of increasing responsibility within Amgen's Oncology Business Unit. Before that he was a management consultant with Deloitte Consulting where he specialized in pharmaceutical marketing and commercial operations.

Comments on this story may be sent to info@m2.com

(C)1994-2012 M2 COMMUNICATIONS http://www.m2.com